Aurinia unveils Positive CHMP Opinion for LUPKYNIS in Europe
Aurinia Pharmaceuticals Inc.(Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending voclosporin (brand name, LUPKYNIS) for marketing authorization to treat adults with active […]
